Clinical trial NCT02310022: A PK and PD Study of Two Formulations of Omega-3 One Gram Capsules
Official title: A Pharmacokinetic and Pharmacodynamic Study of Two Formulations of Omega-3 One Gram Capsules After Single and Multi-Dose Administrations Under Fed Conditions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Hypertriglyceridemia
Lead sponsor: Matinas Biopharma, Inc
Sponsor class: INDUSTRY
First posted: 2014-12-05
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Comparative bioavailability and pharmacodynamics effects of MAT9001 versus an active omega-3 medication comparator.

Detailed description: The primary objective is to determine the comparative bioavailability and pharmacodynamics effects of single and multiple doses of MAT9001 versus an active omega-3 medication comparator.

Eligibility criteria: Inclusion Criteria:

Subjects must fulfil all of the following inclusion criteria to be eligible for participation in the study, unless otherwise specified:

1. Adult male or female subject, 18-70 years of age, inclusive.
2. Light- or non-smoking, male and female subjects, 18 to 70 years of age. Note: subjects that regularly smoke greater than 10 cigarettes per day will not be considered light-smokers and should not be included. Additionally, the use of any cigars, pipes, vapor inhalers or any other tobacco containing product is prohibited within 6 months prior to drug administration.
3. Body mass index (BMI) ≥ 19 and ≤ 40 (kg/m2).
4. No clinically significant findings in vital signs measurements. The acceptable range for seated systolic blood pressure is 90-150 mmHg and for diastolic blood pressure is 50-95 mmHg.
5. No clinically significant abnormal laboratory values that, in the opinion of the investigator, would compromise the subject's safety or the integrity of the study results.
6. Either have: elevated triglyceride levels (2.26 to 4.52 mmol/L \[200 to 400 mg/dL\]), or · triglyceride levels 2.26 to 3.95 mmol/L (200 to 350 mg/dL) and are on stable statin therapy.
7. Total cholesterol levels ≤ 7.75 mmol/L (≤ 300 mg/dL).
8. Hemoglobin ≥ 135 g/L for males or ≥ 120 g/L for females at screening.
9. No clinically significant findings in a 12-lead electrocardiogram (ECG)
10. Have no significant diseases.
11. Willing to use an acceptable, effective method of contraception.
12. Be informed of the nature of the study and give written consent prior to any study procedure.
13. Have no clinically significant findings from a physical examination.

Exclusion Criteria:

Subjects may be excluded from the study if there is evidence of any of the following criteria at screening, check-in, or at any time during the study, as appropriate:

1. History or presence of significant cardiovascular, pulmonary, hepatic, renal, haematological, gastrointestinal (GI), endocrine, immunologic, dermatologic, neurological, or psychiatric disease in the opinion of the PI.
2. Personal or familial history of bleeding disorder(s), thromboembolic disease, clinical GI bleeding, or any history of GI surgery except uncomplicated appendectomy or cholecystectomy, or colorectal surgery for polyps, nonmalignant tumors, or diverticula.
3. Positive urine drug/alcohol testing at screening or check-in.
4. Positive result for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibodies (HCV).
5. History or presence of alcoholism or drug abuse within the past 2 years.
6. Known sensitivity or allergy to fish, shellfish, gelatin or omega-3 products.
7. Subject is a female who is pregnant or lactating.
8. Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days prior to drug administration
9. Donation of blood or significant blood loss within 56 days prior to check- in.
10. Participation in another clinical trial within 30 days prior drug administration.

Primary outcomes:
measure: Bioavailability comparison after single and multiple doses over a 24 hour period at day 1 and day 14
timeFrame: 14 Days
Secondary outcomes:
measure: Comparison of baseline changes of triglycerides and other related lipid protein parameter levels over 14 days
timeFrame: 14 Days
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Pharma Medica Reserach Inc
state: Ontario
Study officials:
affiliation: Pharma Medica Research, Inc.
name: Eric Chen, MD
role: STUDY_DIRECTOR
References:
citation: Maki KC, Bobotas G, Dicklin MR, Huebner M, Keane WF. Effects of MAT9001 containing eicosapentaenoic acid and docosapentaenoic acid, compared to eicosapentaenoic acid ethyl esters, on triglycerides, lipoprotein cholesterol, and related variables. J Clin Lipidol. 2017 Jan-Feb;11(1):102-109. doi: 10.1016/j.jacl.2016.10.010. Epub 2016 Oct 18.